Previsioni

Il prezzo obiettivo medio degli analisti è +17,74€ (+345,73%). La mediana è +15,02€ (+277,39%).

Acquista	13
Mantieni	6
Vendi	0

Notizie Vai al feed delle notizie

EyePoint: DURAVYU misses primary endpoint in Phase‑3 study for wet AMD

The Phase‑3 LUGANO study of DURAVYU did not meet the primary endpoint of change in best‑corrected visual acuity versus aflibercept in the full dataset. After excluding an asymmetric cohort of nine patients, an ad‑hoc analysis showed nominal non‑inferiority (p=0.0096). Key secondary endpoints were met: DURAVYU reduced treatment burden by 42% (on average two fewer injections through week 56) and many patients remained without additional treatment for weeks; safety data showed no relevant differences versus the control group. EyePoint expects LUCIA topline data in Q4 2026 and, depending on those results, aims for an FDA filing in H1 2027. » Altro su de.investing.com
Guggenheim names Eyepoint Pharmaceuticals top pick in biotech sector

Guggenheim has designated Eyepoint Pharmaceuticals as its top pick in the biotech sector and set a $68 price target based on a sum-of-the-parts net present value analysis. The valuation factors in Duravyu for retinal diseases, the expected cash position at end-2025 and near-term clinical catalysts. Top-line data from the Phase III LUGANO study are still expected in August 2026, and the LUCIA study is slated for Q4 2026; Guggenheim expects the non-inferiority primary endpoint to be met and views the commercial launch as promising. » Altro su de.investing.com
Eyepoint expects phase III wet AMD readouts mid-year, DME enrollment on track

Eyepoint said phase III top-line data for its wet AMD program (LUGANO then LUCIA) are expected beginning mid-year, pursuing a non-inferiority pathway versus on-label 2 mg aflibercept with a focus on six-month redosing and reduced treatment burden. The company reported two positive DSMC reviews, low ~5% discontinuation, and highlighted vorolanib’s multi-mechanism profile (VEGF, PDGF, JAK1/IL‑6) as a potential differentiator. Its phase III DME program (COMO and CAPRI) is rapidly enrolling with over one-third of patients enrolled and full enrollment targeted in Q3 2026; DME top-line data are expected in H2 2027. Eyepoint ended Q1 with $223 million in cash and investments, posted a net loss of $85 million, and expects current cash to fund operations into Q4 2027. » Altro su finance.yahoo.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, EyePoint Pharmaceuticals ha registrato ricavi pari a 444,24k€ e un utile netto di −82,78M€

(EUR)	giu 2026	YoY
Ricavi	+444,24k	90,18%
Utile lordo	+444,24k	89,87%
Utile netto	−82,78M	64,18%
EBITDA	−81,61M	63,61%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+360,10M€
Numero di azioni	83,84M
Massimo/minimo a 52 settimane	+16,40€ - +3,39€
Dividendi	No
Beta	1,74
Rapporto P/E	−1,34
Rapporto PEG	+0,04
Rapporto P/B	+2,60
Rapporto P/S	+150,46

Profilo aziendale

EyePoint Pharmaceuticals, Inc. ist ein pharmazeutisches Unternehmen, das ophthalmologische Produkte für die Behandlung von Augenkrankheiten in den Vereinigten Staaten, China und Großbritannien entwickelt und vertreibt. Das Unternehmen bietet ILUVIEN, ein injizierbares Mikro-Insert mit verzögerter Wirkstofffreisetzung zur Behandlung des diabetischen Makulaödems, YUTIQ, ein Fluocinolonacetonid-Implantat zur intravitrealen Injektion für die Behandlung chronischer, nicht-infektiöser Uveitis, die das hintere Augensegment betrifft, und DEXYCU, eine Dexamethason-Suspension für das Auge, zur Behandlung postoperativer Augenentzündungen, einschließlich der Behandlung nach Kataraktoperationen. Darüber hinaus entwickelt das Unternehmen EYP-1901, eine zweimal jährlich bioerodierbare Formulierung eines Tyrosinkinase-Hemmers zur Behandlung der feuchten altersbedingten Makuladegeneration, der diabetischen Retinopathie und des Netzhautvenenverschlusses, sowie YUTIQ50 zur Behandlung der chronischen, nicht-infektiösen Uveitis, die den hinteren Teil des Auges betrifft. Das Unternehmen unterhält strategische Kooperationen mit Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics und Equinox Science, LLC. Darüber hinaus besteht eine kommerzielle Allianz mit ImprimisRx PA, Inc. zur gemeinsamen Vermarktung von DEXYCU zur Behandlung von postoperativen Entzündungen nach Augenoperationen. Das Unternehmen war früher als pSivida Corp. bekannt und änderte im März 2018 seinen Namen in EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc. wurde 1987 gegründet und hat seinen Hauptsitz in Watertown, Massachusetts.

Nome	EyePoint Pharmaceuticals
CEO	Jay S. Duker
Sede centrale	Watertown, ma Stati Uniti
Sito web	eyepointpharma.com
Industria	Attrezzature e forniture sanitarie
Quotazione in borsa	27/01/2005
Dipendenti	214